Upgrade to SI Premium - Free Trial

Savara (SVRA)

5.06 -0.03 (0.59%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/6/26)

Latest Headlines

Form 8-K Savara Inc For: Jun 04 June 8, 2026 4:16 PM - SEC Filing Savara names Robert Lutz as chief operating and financial officer June 8, 2026 4:05 PM - StreetInsider Savara Announces Chief Financial and Administrative Officer Transition June 8, 2026 4:05 PM - BizWire Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference May 27, 2026 4:05 PM - BizWire Savara presents biomarker data from phase 3 trial at ATS conference May 20, 2026 8:15 AM - StreetInsider Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thor May 20, 2026 8:15 AM - BizWire Savara presents long-term data from molgramostim trial extension May 19, 2026 2:15 PM - StreetInsider Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonar May 19, 2026 2:15 PM - BizWire Savara reports improved exercise capacity in aPAP drug trial May 18, 2026 2:55 PM - StreetInsider Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) May 18, 2026 2:55 PM - BizWire Savara (SVRA) Misses Q1 EPS by 3c May 12, 2026 5:06 PM - StreetInsider Form 10-Q Savara Inc For: Mar 31 May 12, 2026 4:06 PM - SEC Filing Savara Reports First Quarter Financial Results and Provides Business Update May 12, 2026 4:05 PM - BizWire Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference May 11, 2026 4:05 PM - BizWire Form ARS Savara Inc For: Dec 31 April 24, 2026 4:27 PM - SEC Filing Form DEFA14A Savara Inc April 24, 2026 4:25 PM - SEC Filing Form DEF 14A Savara Inc For: Jun 04 April 24, 2026 4:23 PM - SEC Filing Oppenheimer Assumes Savara (SVRA) at Outperform April 24, 2026 6:14 AM - StreetInsider Savara Announces New Employment Inducement Grant April 17, 2026 4:05 PM - BizWire FDA extends review for Savara's molgramostim drug application by three months April 15, 2026 4:05 PM - StreetInsider Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune April 15, 2026 4:05 PM - BizWire Savara to present trial data at 2026 respiratory disease conference April 14, 2026 8:05 AM - StreetInsider Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference April 14, 2026 8:05 AM - BizWire Form PRE 14A Savara Inc For: Jun 04 April 10, 2026 4:19 PM - SEC Filing Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis April 7, 2026 9:31 AM - BizWire Savara receives UK regulatory acceptance for rare lung disease drug April 7, 2026 8:08 AM - StreetInsider Citizens Reiterates Market Outperform Rating on Savara (SVRA), Highlights Molbreevi Potential March 31, 2026 4:27 AM - StreetInsider Jefferies on Savara (SVRA): 'We remain 90% confident in Molbreevi's US approval by Aug 22, 2026' March 30, 2026 3:41 PM - StreetInsider Savara receives EMA validation for MOLBREEVI application in rare lung disease March 30, 2026 8:05 AM - StreetInsider Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) March 30, 2026 8:05 AM - BizWire Form 4 Savara Inc For: Mar 18 Filed by: Lowrance David L March 20, 2026 4:16 PM - SEC Filing H.C. Wainwright Reiterates Buy Rating on Savara (SVRA): 'well positioned ahead of the August PDUFA date' March 16, 2026 11:22 AM - StreetInsider Form 8-K Savara Inc For: Mar 10 March 13, 2026 8:30 AM - SEC Filing Form 10-K Savara Inc For: Dec 31 March 13, 2026 8:11 AM - SEC Filing Savara submits BLA for MOLBREEVI with FDA priority review set for August March 13, 2026 8:06 AM - StreetInsider Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update March 13, 2026 8:05 AM - BizWire Full Article List